Geneva, June 4 -- International Clinical Trials Registry received information related to the study (ISRCTN11493807) titled 'Phase I trial HMR code: 25-001' on May 16.
Study Type: Interventional
Study Design:
Phase I safety, pharmacokinetics and pharmacodynamics trial in up to 84 healthy participants (Other)
Primary Sponsor: Dr Falk Pharma GmbH
Condition:
Healthy volunteers
Other
Intervention:
The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.
Recruitment Status: Recruiting
Phase: Phase I
Date of First Enrollment: 03/06/2025
Target Sample Size: 84
Countries o...